Barbara Palumbo

Prof. Barbara Palumbo

Section of Nuclear Medicine and Health Physics, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Francesco BianconiFrancesco Bianconi
Francesco Bianconi
IPIsabella Palumbo
Isabella Palumbo
ASAngela Spanu
Angela Spanu
Susanna Maria Francesca NuvoliSusanna Maria Francesca Nuvoli
Susanna Maria Francesca Nuvoli
MFMario luca Fravolini
Mario luca Fravolini
BPBarbara Palumbo
Barbara Palumbo
Quantitative extraction of imaging features from medical scans (‘radiomics’) has attracted a lot of research attention in the last few years. The literature has consistently emphasized the potential use of radiomics for computer-assisted diagnosis, as well as for predicting survival and response to treatment. Radiomics is appealing in that it enables full-field analysis of the lesion, provides nearly real-time results, and is non-invasive. Still, a lot of studies suffer from a series of drawbacks such as lack of standardization and repeatability. Such limitations, along with the unmet demand for large enough image datasets for training the algorithms, are major hurdles that still limit the application of radiomics on a large scale. In this paper, we review the current developments, potential applications, limitations, and perspectives of PET/CT radiomics with specific focus on the management of patients with lung cancer.

8 April 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Luca FilippiLuca Filippi
Luca Filippi
Francesco BianconiFrancesco Bianconi
Francesco Bianconi
OSOrazio Schillaci
Orazio Schillaci
ASAngela Spanu
Angela Spanu
BPBarbara Palumbo
Barbara Palumbo
Novel therapeutic approaches, consisting of immune check-point inhibitors (ICIs) and molecularly targeted therapy, have thoroughly changed the clinical management of malignant melanoma (MM), the most frequent and deadly skin cancer. Since only 30–40% of MM patients respond to ICIs, imaging biomarkers suitable for the pre-therapeutic stratification and response assessment are warmly welcome. In this scenario, positron emission computed tomography (PET/CT) with 18F-fluorodeoxyglucose (18F-FDG) has been successfully utilized for advanced MM staging and therapy response evaluation. Furthermore, several PET-derived parameters (SUVmax, MTV, TLG) were particularly impactful for the prognostic evaluation of patients submitted to targeted and immunotherapy. In this review, we performed a web-based and desktop research on the clinical applications of 18F-FDG PET/CT in MM, with a particular emphasis on the various metabolic criteria developed for interpreting PET/CT scan in patients undergoing immunotherapy or targeted therapy or a combination of both. Furthermore, the emerging role of radiomics, a quantitative approach to medical imaging applying analysis methodology derived by the field of artificial intelligence, was examined in the peculiar context, putting a particular emphasis on the potential of this discipline to support clinicians in the delicate process of building patient-tailored pathways of care.

15 September 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
BPBarbara Palumbo
Barbara Palumbo
Francesco BianconiFrancesco Bianconi
Francesco Bianconi
IPIsabella Palumbo
Isabella Palumbo
MFMario luca Fravolini
Mario luca Fravolini
MMMatteo Minestrini
Matteo Minestrini
ASAngela Spanu
Angela Spanu
In this paper, we investigate the role of shape and texture features from 18F-FDG PET/CT to discriminate between benign and malignant solitary pulmonary nodules. To this end, we retrospectively evaluated cross-sectional data from 111 patients (64 males, 47 females, age = 67.5 ± 11.0) all with histologically confirmed benign (n=39) or malignant (n=72) solitary pulmonary nodules. Eighteen three-dimensional imaging features, including conventional, texture, and shape features from PET and CT were tested for significant differences (Wilcoxon-Mann-Withney) between the benign and malignant groups. Prediction models based on different feature sets and three classification strategies (Classification Tree, k-Nearest Neighbours, and Naïve Bayes) were also evaluated to assess the potential benefit of shape and texture features compared with conventional imaging features alone. Eight features from CT and 15 from PET were significantly different between the benign and malignant groups. Adding shape and texture features increased the performance of both the CT-based and PET-based prediction models with overall accuracy gain being 3.4–11.2 pp and 2.2–10.2 pp, respectively. In conclusion, we found that shape and texture features from 18F-FDG PET/CT can lead to a better discrimination between benign and malignant lung nodules by increasing the accuracy of the prediction models by an appreciable margin.

Verified
Journal Article
Open access
PDF file
BPBarbara Palumbo
Barbara Palumbo
TBTommaso Buresta
Tommaso Buresta
Susanna Maria Francesca NuvoliSusanna Maria Francesca Nuvoli
Susanna Maria Francesca Nuvoli
ASAngela Spanu
Angela Spanu
OSOrazio Schillaci
Orazio Schillaci
IPIsabella Palumbo
Isabella Palumbo
Nuclear medicine techniques (single photon emission computerized tomography, SPECT, and positron emission tomography, PET) represent molecular imaging tools, able to provide in vivo biomarkers of different diseases. To investigate brain tumours and metastases many different radiopharmaceuticals imaged by SPECT and PET can be used. In this review the main and most promising radiopharmaceuticals available to detect brain metastases are reported. Furthermore the diagnostic contribution of the combination of SPECT and PET data with radiological findings (magnetic resonance imaging, MRI) is discussed.

1 December 2014 in Medicine
Verified
Journal Article
Open access
BPBarbara Palumbo
Barbara Palumbo
MFMario Luca Fravolini
Mario Luca Fravolini
TBTommaso Buresta
Tommaso Buresta
FPFilippo Pompili
Filippo Pompili
NFNevio Forini
Nevio Forini
Nicola TambascoNicola Tambasco
Nicola Tambasco
Brain single-photon-emission-computerized tomography (SPECT) with 123I-ioflupane (123I-FP-CIT) is useful to diagnose Parkinson disease (PD). To investigate the diagnostic performance of 123I-FP-CIT brain SPECT with semiquantitative analysis by Basal Ganglia V2 software (BasGan), we evaluated semiquantitative data of patients with suspect of PD by a support vector machine classifier (SVM), a powerful supervised classification algorithm. 123I-FP-CIT SPECT with BasGan analysis was performed in 90 patients with suspect of PD showing mild symptoms (bradykinesia-rigidity and mild tremor). PD was confirmed in 56 patients, 34 resulted non-PD (essential tremor and drug-induced Parkinsonism). A clinical follow-up of at least 6 months confirmed diagnosis. To investigate BasGan diagnostic performance we trained SVM classification models featuring different descriptors using both a “leave-one-out” and a “five-fold” method. In the first study we used as class descriptors the semiquantitative radiopharmaceutical uptake values in the left (L) and right (R) putamen (P) and in the L and R caudate nucleus (C) for a total of 4 descriptors (CL, CR, PL, PR). In the second study each patient was described only by CL and CR, while in the third by PL and PR descriptors. Age was added as a further descriptor to evaluate its influence in the classification performance. 123I-FP-CIT SPECT with BasGan analysis reached a classification performance higher than 73.9% in all the models. Considering the “Leave-one-out” method, PL and PR were better predictors (accuracy of 91% for all patients) than CL and CR descriptors; using PL, PR, CL, and CR diagnostic accuracy was similar to that of PL and PR descriptors in the different groups. Adding age as a further descriptor accuracy improved in all the models. The best results were obtained by using all the 5 descriptors both in PD and non-PD subjects (CR and CL + PR and PL + age = 96.4% and 94.1%, respectively). Similar results were observed for the “five-fold” method. 123I-FP-CIT SPECT with BasGan analysis using SVM classifier was able to diagnose PD. Putamen was the most discriminative descriptor for PD and the patient age influenced the classification accuracy.

8 July 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Luca FilippiLuca Filippi
Luca Filippi
IPIsabella Palumbo
Isabella Palumbo
OBOreste Bagni
Oreste Bagni
OSOrazio Schillaci
Orazio Schillaci
CACynthia Aristei
Cynthia Aristei
BPBarbara Palumbo
Barbara Palumbo
The aims of the present systematic review are to: (1) assess the diagnostic performance of somatostatin receptor (SSR)targeted positron emission tomography (PET) with different tracers and devices in patients affected by meningiomas; and (2) to evaluate the theranostic applications of peptide receptor radionuclide therapy (PRRT) in meningiomas. A systematic literature search according to PRISMA criteria was made by using two main databases. Only studies published from 2011 up to March 2022 in the English language with ≥10 enrolled patients were selected. Following our research strategy, 17 studies were included for the assessment. Fourteen studies encompassed 534 patients, harboring 733 meningiomas, submitted to SSR-targeted PET/CT (n = 10) or PET/MRI (n = 4) for de novo diagnosis, recurrence detection, or radiation therapy (RT) planning (endpoint 1), while 3 studies included 69 patients with therapy-refractory meningiomas submitted to PRRT (endpoint 2). A relevant variation in methodology was registered among diagnostic studies, since only a minority of them reported histopathology as a reference standard. PET, especially when performed through PET/MRI, resulted particularly useful for the detection of meningiomas located in the skull base (SB) or next to the falx cerebri, significantly influencing RT planning. As far as it concerns PRRT studies, stable disease was obtained in the 66.6% of the treated patients, being grade 1–2 hematological toxicity the most common side effect. Of note, the wide range of the administered activities, the various utilized radiopharmaceuticals (90Y-DOTATOC and/or 177Lu-DOTATATE), the lack of dosimetric studies hamper a clear definition of PRRT potential on meningiomas’ management.